J Korean Diabetes.  2025 Mar;26(1):1-4. 10.4093/jkd.2025.26.1.1.

Optimal Management of Diabetic Kidney Disease

• Jeon JH

• KMID: 2567083
• DOI: http://doi.org/10.4093/jkd.2025.26.1.1

Abstract

Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease (CKD) and end-stage renal disease in Korea, with an increasing prevalence due to the aging population and rising diabetes cases. While glycemic control has improved, DKD prevention requires a multifaceted approach addressing blood pressure, lipid levels, and lifestyle factors. This study reviews the current status of DKD management in Korea and proposes strategies for optimization. Patients with DKD frequently present with comorbidities such as hypertension, dyslipidemia, and obesity. Although renin-angiotensin-aldosterone system inhibitors are commonly prescribed, the utilization of newer therapies, such as sodium glucose cotransporter 2 (SGLT2) inhibitors, remains low. Effective management necessitates comprehensive risk factor control, careful medication selection, and public education on the risk of nephrotoxic drugs and unverified supplements. Policy changes are needed to improve access to advanced therapies and personalized care. Expanding the use of SGLT2 inhibitors, glucagon-like peptide-1 receptor agonists, and mineralocorticoid receptor antagonists can delay disease progression and enhance patient outcomes. Additionally, public education and monitoring systems are critical to prevent the misuse of nephrotoxic agents. In conclusion, DKD is a growing public health challenge in Korea. Collaborative efforts among healthcare providers, policymakers, and patients are needed to improve patient care through integrated, data-driven strategies.

Keyword

Diabetes mellitus; Diabetic nephropathies; Therapeutics

Reference

1.Lee YJ., Kim YG. The current status of diabetic nephropathy in Korea. Korean J Med. 2009. 77:667–9.

2.Kim NH., Seo MH., Jung JH., Han KD., Kim MK., Kim NH. 2023 Diabetic kidney disease fact sheet in Korea. Diabetes Metab J. 2024. 48:463–72.

3.Lee H., Lee M., Park G., Khang AR. Prevalence of chronic diabetic complications in patients with type 2 diabetes mellitus: a retrospective study based on the National Health Insurance Service-National Health Screening Cohort in Korea, 2002~2015. Korean J Adult Nurs. 2022. 34:39–50.

4.Premaratne E., Macisaac RJ., Tsalamandris C., Panagiotopoulos S., Smith T., Jerums G. Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate. Diabetologia. 2005. 48:2486–93.

5.United States Renal Data System. 2022 Annual data report. Available from: https://usrds-adr.niddk.nih.gov/2022.

6.Yoon JS. Screening and management of diabetic nephrop-athy. J Korean Diabetes. 2013. 14:19–22.

7.Moon JS., Kang S., Choi JH., Lee KA., Moon JH., Chon S, et al. 2023 Clinical practice guidelines for diabetes management in Korea: full version recommendation of the Korean Diabetes Association. Diabetes Metab J. 2024. 48:546–708.

8.Chung S. Synopsis of the Korean Society of Nephrology 2023 practical recommendations for the management of diabetic kidney disease. Korean J Med. 2023. 98:270–82.

9.Kim DH., Hyun YY., Cha JJ., Lee S., Lee HK., Choi JW, et al. Kidney Health Plan 2033 in Korea: bridging the gap between the present and the future. Kidney Res Clin Pract. 2024. 43:8–19.